Viking Therapeutics, Inc. (VKTX)
| Market Cap | 4.42B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -472.34M |
| Shares Out | 116.11M |
| EPS (ttm) | -4.16 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,782,562 |
| Open | 36.36 |
| Previous Close | 36.99 |
| Day's Range | 36.13 - 38.48 |
| 52-Week Range | 22.96 - 43.15 |
| Beta | 0.68 |
| Analysts | Strong Buy |
| Price Target | 92.58 (+143.38%) |
| Earnings Date | Jul 22, 2026 |
About VKTX
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. The company develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II c... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 20 analysts, the average rating for VKTX stock is "Strong Buy." The 12-month stock price target is $92.58, which is an increase of 143.38% from the latest price.
News
Viking catalysts include VK3019, VK2735 readouts in Q3, says Raymond James
Raymond James tells investors in a research note that Viking Therapeutics (VKTX) initiated a Phase 1 single ascending dose study of VK3019, a dual amylin and calcitonin receptor agonist for…
Viking Therapeutics begins Phase 1 SAD clinical trial of VK3019
Viking Therapeutics (VKTX) announced the initiation of a Phase 1 single ascending dose, or SAD, clinical trial of VK3019, an investigational dual amylin and calcitonin receptor agonist, or DACRA. VK30...
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults
Single ascending dose study evaluating safety, tolerability, and pharmacokinetics of VK3019 Potential to further expand Viking's treatment options for weight loss SAN DIEGO, June 24, 2026 /PRNewswire/...
Viking Therapeutics management to meet with B. Riley
Meeting to be held in Denver on June 22 hosted by B. Riley.
Viking Therapeutics names Hubert Chen, M.D., as Chief Medical Officer
Viking Therapeutics (VKTX) announced the appointment of Hubert Chen, M.D., as chief medical officer. Dr. Chen brings more than two decades of leadership experience in senior executive roles spanning d...
Viking Therapeutics Announces Appointment of Hubert C. Chen, M.D.
Experienced Biotech Leader with More than Two Decades of Experience Advancing Therapies from Discovery through Regulatory Approval SAN DIEGO, June 11, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (V...
Viking Therapeutics Slides: Corporate presentation
Viking Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 7, 2026.
Viking Therapeutics Transcript: Jefferies Global Healthcare Conference 2026
Phase III obesity trials are fully enrolled, with data expected in 2027, and an oral formulation is advancing to phase III later this year. Maintenance dosing and a novel amylin agonist are in development, while strong cash reserves support ongoing trials and commercial planning.
Viking Therapeutics initiated with a Buy at Lake Street
Lake Street initiated coverage of Viking Therapeutics (VKTX) with a Buy rating and $89 price target based on the market opportunity for the company’s lead clinical asset, VK2735 in obesity.
Viking Therapeutics assumed with a Buy at Truist
Truist assumed coverage of Viking Therapeutics (VKTX) with a Buy rating with a price target of $83, up from $75. The firm is positive on the stock as a differentiated…
Viking Therapeutics to Participate at Upcoming Investor Conferences
SAN DIEGO, May 21, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and ...
Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial
Viking Therapeutics (VKTX) presented additional data from its Phase 2 VENTURE-Oral Dosing trial evaluating the oral tablet formulation of VK2735 at the European Congress on Obesity in Istanbul. VK2735...
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026
Oral VK2735 demonstrated early, progressive weight loss from Week 1 through Week 13 without a plateau Dose-dependent weight loss observed across all VK2735 cohorts, with the highest dose achieving a m...
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026
Poster Presentations Highlight Data from 13-Week Phase 2 VENTURE-Oral Trial of VK2735 and Participant Characteristics from Phase 3 VANQUISH-1 Trial of Subcutaneous VK2735 SAN DIEGO, May 5, 2026 /PRNew...
Viking Therapeutics price target lowered to $100 from $105 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse lowered the firm’s price target on Viking Therapeutics (VKTX) to $100 from $105 and keeps an Overweight rating on the shares. The firm expects subQ…
Viking Therapeutics price target lowered to $95 from $99 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Viking Therapeutics (VKTX) to $95 from $99 and keeps an Overweight rating on the shares following the company’s Q1 report. Published first…
Viking Therapeutics reports Q1 EPS ($1.37), consensus (91c)
Cash, cash equivalents and short-term investments at quarter end were $603M vs. $706M at previous quarter end. “We are excited to report that the advances and strong momentum Viking created…
Viking Therapeutics Earnings Call Transcript: Q1 2026
Q1 2026 saw major clinical progress for VK2735 in both injectable and oral forms, with phase III trials fully enrolled and a maintenance dosing study expanded. R&D expenses drove a higher net loss, but cash reserves remain strong, supporting operations into 2028.
Viking Therapeutics Earnings release: Q1 2026
Viking Therapeutics released its Q1 2026 earnings on April 29, 2026, summarizing the period's financial results.
Viking Therapeutics Quarterly report: Q1 2026
Viking Therapeutics has published its Q1 2026 quarterly earnings report on April 29, 2026.
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today -- Phase 3 VANQUISH Trials for Subcutaneous VK2735 in Obesity Advance; VANQUISH-1 and VANQUISH-2 Trials Fully Enrolled -- -- Initiation of Phase 3 Oral...
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026
Conference Call Scheduled for Wednesday, April 29 at 4:30 p.m. Eastern Time SAN DIEGO, April 22, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharm...
Viking Therapeutics Proxy statement: Proxy filing
Viking Therapeutics filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Viking Therapeutics Proxy statement: Proxy filing
Viking Therapeutics filed a proxy statement on April 1, 2026, providing details for shareholder voting and corporate governance matters.
Viking Therapeutics completes enrollment in Phase 3 VANQUISH-2 trial of VK2735
Viking Therapeutics (VKTX) announced the completion of patient enrollment in its Phase 3 VANQUISH-2 clinical trial of subcutaneous VK2735, the company’s dual agonist of the glucagon-like peptide 1 and...